TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00004039
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02142634
Drug: Placebo granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: per day
Study: NCT00383240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo metered dose inhaler twice a day for 26 weeks
Study: NCT02042638
Drug: hCG 1500 IU three times a week
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02042638
Drug: Pregnyl (hCG) ampule 1500 IU/three times a week
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002796
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00002796
Drug: indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00136032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage based on age and estrogen status ranging from 3 to 6 mcg/kg/day
Study: NCT01339624
Drug: FENTANYL
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FENTANYL CITRATE, NASAL, 3 GAMMA/KG
Study: NCT01339624
Drug: Ketorolac Tromethamine AND morphine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine 5 MG diluted in saline solution 100 ml followed by 2-ml ampoule of ketorolac 30 MG in saline solution 100 ml was infused:
Study: NCT00406406
Drug: SKI-606
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002716
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002716
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02830542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
Study: NCT00695500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, 0 mg per day for 3 weeks
Study: NCT01836016
Drug: Bufei granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.
Study: NCT02443506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
Study: NCT01836016
Drug: conventional medicine + TCM
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
Study: NCT04199455
Drug: Integrative Treatment (EPACH Recipe Granules + NQABC Recipe Granules)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of EPACH recipe granules, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of NQABC recipe granules, dissolved with 200ml of boiled water, twice a day.
Study: NCT04199455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomly assigned to the intervention group will receive recipe simulators as placebo. EPACH and NQABC granules and recipe simulators are indistinguishable, identical in size, shape, color, appearance. Placebo is no decocting granules contain 5% original formula, 20% bitter gourd extract, 75% dextrin, and caramel color. Those who are assigned to the control group will be given placebo and guideline-based standard stroke treatment.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of recipe simulator, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of recipe simulator, dissolved with 200ml of boiled water, twice a day.
Study: NCT02671318
Drug: Maintenance of the current regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
Study: NCT03230383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for PF-06865571 for each cohort.
Study: NCT02902653
Drug: Vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal delivery system of 10mg of dinoprostone
Study: NCT04546022
Drug: Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00151905
Drug: 3 % hypertonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01143545
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 g po bid
Study: NCT01143545
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg po bid
Study: NCT00002547
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002547
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00889837
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staccato Placebo, inhalations x 2 , 10 hours apart
Study: NCT03304756
Drug: CAP
Normalized name: CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
Study: NCT01542021
Drug: androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01585298
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04699097
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg tablet, 5 ml / 200 mg 30 ml suspension
Study: NCT01590771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to sitagliptin oral tablet once daily for 24 weeks
Study: NCT02929719
Drug: Aczone Gel 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel
Study: NCT02929719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel
Study: NCT03075501
Drug: Stimulant or sedative
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS+ for paired, CS0 for unpaired
Study: NCT03075501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS- for paired, CS0 for unpaired
Study: NCT01251822
Drug: PEG 3350 plus electrolytes
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each sachet of PEG 3350 is dissolved in 125 mL of water. Patients receive two sachets of PEG 3350 plus electrolytes followed by two placebo tablets for the first 14 days, after which dosage adjustment is permitted, according to effect. Each patient is treated for 28 days in total.
Study: NCT02794025
Drug: natural saline
Normalized name: XYNASE Natural Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group also received natural saline via a micro pump,
Study: NCT03790540
Drug: Topical Benzocaine 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzocaine 20% gel on the mucosal injection site prior to injection
Study: NCT02189577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
Study: NCT00155883
Drug: Taxteral
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00155883
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01262118
Drug: CP-690,550 (tasocitinib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
Study: NCT02604797
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient-controlled intravenous analgesia
Study: NCT00694135
Drug: EGP-437 1.6 mA-min at 0.4 with EyeGate® II System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System
Study: NCT00694135
Drug: EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System
Study: NCT00694135
Drug: EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
Study: NCT01802515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
Study: NCT04321278
Drug: Hydroxychloroquine + azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] + azithromycin \[500mg 1x/day\]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
Study: NCT01554293
Drug: PBL 1427 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBL 1427 capsules 20 mg and 150 mg, single dose
Study: NCT03756064
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet: 400mg orally daily
Study: NCT00056329
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for three years
Study: NCT00047541
Drug: Alcon Investigational Agent
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01980524
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02413593
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT03845075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Part 1 subjects will be randomized to matching placebo tesofensine and placebo metoprolol
Study: NCT01209741
Drug: MK-0974 5Mo5C
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
Study: NCT00935259
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg once daily for 2 weeks
Study: NCT00935259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
Study: NCT00904683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously (IV) every 4 weeks for 80 weeks
Study: NCT00001677
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00829660
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
Study: NCT02801409
Drug: General anesthesia alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.
Study: NCT02937896
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg intravenous Ketorolac.
Study: NCT02937896
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1cc intravenous Normal Saline.
Study: NCT02937896
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 puffs nasal Normal Saline.
Study: NCT04515628
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT00738985
Drug: ezetimibe/simvastatin 10/20 mg + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo (sugar tablets) for up to 22 weeks.
Study: NCT00738985
Drug: ezetimibe/simvastatin 10/20 mg + MK0524A
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe (+) simvastatin 10/20 mg for 18 weeks. Tablets
Study: NCT02411708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single two-hour infusion of placebo
Study: NCT00409409
Drug: 300 IR grass pollen allergen extract tablet
Normalized name: orchard grass pollen extract 300 IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Study: NCT00409409
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Study: NCT06382571
Drug: Renin-Angiotensin System Inhibitor
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00716547
Drug: ketoprofen in Diractin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg (b.i.d.)
Study: NCT00716547
Drug: ketoprofen in Diractin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg (b.i.d.)
Study: NCT00716547
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg (b.i.d.)
Study: NCT02970032
Drug: Real time heparin dose adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
Study: NCT02970032
Drug: Standard heparin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be placed on heparin infusions per their surgeon's discretion.
Study: NCT04178512
Drug: Drug:dexamethasone in group Dexamethasone,fentanyl in group Fentanyl,normal saline 0.9%in group Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: prevention of shivering after spinal anesthesia in patients undergoing trans urethral prostatectomy through injection of spinal additives
Study: NCT01658956
Drug: GCSF administration on days 8 and 12 after chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00871351
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
Study: NCT01486758
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.
Study: NCT01486758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01432522
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Intranasal epinephrine 5 mg /spray~2. Intramuscular epinephrine 0.3 mg~3. Intranasal saline spray
Study: NCT01003171
Drug: MCS-2 soft-gel capsule
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MCS-2 30 mg/day
Study: NCT01175772
Drug: Cytophosphan, Celecoxib, Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic Chemotherapy as maintenance treatment for patients with Ovarian Cancer~* Cytophosphan tab 50 mg -1x1 per day, continuous~* Celecoxib tab 200 mg - 1x2 per day, continuous~* Methotrexate tab 2.5 mg - 1x2 per day, 2 days weekly
Study: NCT00468130
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive tablet made to resemble active tablet~Subjects under 40 kg will be started on 2.5mg per day of placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
Study: NCT02471859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at various doses, depending on the cohort and treatment period
Study: NCT00436956
Drug: AZD2171
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral daily for 28 days
Study: NCT04105972
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet for oral administration.
Study: NCT04105972
Drug: TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) tablet for oral administration.
Study: NCT01732146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02455999
Drug: SYL1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYL1001 eye drops dose C administration for 10 consecutive days
Study: NCT02455999
Drug: SYL1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYL1001 eye drops dose D administration for 10 consecutive days
Study: NCT02455999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops administration for 10 consecutive days
Study: NCT00238992
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01095133
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time
Study: NCT01095133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form: intraesophageal saline infusion dosage: normal Saline (0.91% w/v of NaCl) duration: 5 minutes given once frequency: 1 time
Study: NCT00878553
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet at bedtime
Study: NCT04482192
Drug: Systemic analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic analgesia (SA) group receive 1gm paracetamol and 30 mg ketorolac by intravenous infusion every 6 hours for 3 days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
Study: NCT04711486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo without any exipients.
Study: NCT04706793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks
Study: NCT00204269
Drug: Testosterone Gel Wolff
Normalized name: testosterone Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01551069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT04063046
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia is induced with propofol (0.5-2mg / kg), remifentanil (4-8㎍ / kg / hr) and rocuronium (0.4 \~ 0.6 mg / kg) involving laryngeal mask(supraglottic airway device) insertion or endotracheal intubation. Anesthesia is maintained with 1.0-2.5% sevoflurane and remifentanil.
Study: NCT00510146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets, oral, once daily at bedtime, 6 weeks
Study: NCT00066846
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00066846
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04181489
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 mg/m2 d1
Study: NCT04181489
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m2 d1
Study: NCT04181489
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 60mg/m2 d1-5
Study: NCT00947141
Drug: Stop treatment when 2 levels CMV PCR <3,000 copies / ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Viral load \> 3,000 copies/ml. Participants are randomised to treat until \< 3,000 copies/ml on 2 occasions or treat until \<200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B
Study: NCT00336336
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg die per os
Study: NCT00336336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram c. per os
Study: NCT00336336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg c. per os